US-based biotechnology firm Thermo Fisher Scientific has unveiled a new capillary electrophoresis (CE) system called Applied Biosystems SeqStudio Genetic Analyser.
Intended for Sanger sequencing and fragment analysis, the low-throughput, cartridge-based system has applications in a variety of divisions, including oncology research, species identification, genome editing and human cell line authentication.
The new device features a cartridge with a combination of capillary array, polymer reservoir and anode buffer to allow easy preparation and quick processing.
The analyser also includes access to individualised protocols, intuitive touchscreen and connectivity to the firm’s cloud to enable remote setup and monitoring, easy collaboration and data analysis.
Thermo Fisher Scientific Genetic Analysis vice-president and general manager Kim Kelderman said: "Sanger sequencing using CE, which is celebrating its 40th anniversary this year, is the gold standard sequencing technology.
“It helped discover novel biological findings such as the first breast cancer gene (BRCA1) and was used to complete the Human Genome Project in 2003."
The device facilitates operation of both sequencing and fragment analysis on the same CE plate, resulting in new analyses opportunities such as a combination of a locus screening test and a copy number variability test on the same plate.
Currently in use by certain North American, EMEA, Japanese and Chinese customers, the Applied Biosystems SeqStudio Genetic Analyser will be available in other international markets from the second half of this year.
Image: The new SeqStudio Genetic Analyser. Photo: courtesy of PRNewsfoto/Thermo Fisher Scientific Inc.